At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Mar 23, 2026 at 07:30 ET
Lexicon Pharmaceuticals announced that Novo Nordisk has initiated a Phase 1 clinical trial for LX9851, a first-in-class oral obesity candidate discovered by Lexicon. As a result, Lexicon earned a $10 million milestone payment and remains eligible for up to $1 billion in total milestones plus royalties on future sales.
- Novo Nordisk initiated a Phase 1 study of LX9851, triggering a $10 million milestone payment to Lexicon.
- Lexicon is eligible for up to $1 billion in total upfront and milestone payments, including a third $10 million milestone potentially this year.
- LX9851 is a novel oral non-incretin drug targeting obesity with preclinical data showing enhanced weight loss when combined with semaglutide.
- The Phase 1 trial will evaluate safety, tolerability, and pharmacokinetics in 96 individuals with overweight or obesity, with completion expected in Q1 2027.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access